Christopher Brightling on tezepelumab in patients with moderate-to-severe uncontrolled asthma

The Lancet Respiratory Medicine in conversation with
11/07/2021 13 min
Christopher Brightling on tezepelumab in patients with moderate-to-severe uncontrolled asthma

Listen "Christopher Brightling on tezepelumab in patients with moderate-to-severe uncontrolled asthma"

Descargar episodio

Episode Synopsis

Christopher Brightling discusses the effect of blocking thymic stromal lymphopoietin (TSLP) with tezepelumab in patients with moderate-to-severe uncontrolled asthma.Read the full article:https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00226-5/fulltextContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

More episodes of the podcast The Lancet Respiratory Medicine in conversation with

Finn McQuaid and Matthew Saunders on Tuberculosis and Climate change 30/10/2025
Toby Maher on ENV-101 in patients with idiopathic pulmonary fibrosis 28/09/2025
Guy Brusselle and Celeste Porsbjerg on State-of-the-art insights into prevention, development, and management of asthma 28/09/2025
Joan Soriano on Global Epidemiology of Respiratory Disease 17/07/2025
Carole Mitnick & Lorenzo Guglielmetti on the ENDTB-Q trial 16/07/2025
Lorenzo Guglielmetti parla del trial clinico ENDTB-Q (in Italian) 16/07/2025
Laura Garriga-Grimau on bronchiectasis in children and young people 02/07/2025
Marcus J Schultz and Prashant Nasa on defining and subphenotyping ARDS 04/06/2025
Hjalmar Bouma on sepsis in patients who are immunocompromised 20/05/2025
Simon Wolf on pulmonary embolism in children and adolescents in the US during 2016 and 2019 07/04/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA